[Injectable progesterone in hormone replacement therapy in menopause].
OBJECTIVE
To evaluate activity and tolerability of intramuscular administration of 17-alpha-hydroxyprogesterone caproate (Lentogest-Amsa) in hormone replacement therapy in menopause.


METHODS
Intramuscular slow releasing 17-alpha-hydroxyprogesterone caproate was given to 30 postmenopausal women. Patients were divided into two groups according to the number of monthly doses (1 or 2).


RESULTS
In both groups of patients a regular monthly bleeding was obtained. Echographic assessment did not show abnormal endometrial thickness.


CONCLUSIONS
The results of this study have pointed out the efficacy of intramuscular progesterone-caproate administration with a better compliance in the single dose group.
Patacchiola
F
F
Dipartimento di Discipline Chirurgiche, Università degli Studi de L'Aquila, Italia.
Porzio
G
G
Carta
G
G
Mascaretti
G
G
Palermo
P
P
Silani
S
S
Di Stefano
L M
LM
Moscarini
M
M
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000279:Administration, Cutaneous; D000367:Age Factors; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D008593:Menopause; D008875:Middle Aged; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors
D003692:Delayed-Action Preparations; D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol